Rodrigo Mansilla-Vivar

Dr. Rodrigo Mansilla-Vivar

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
RMRodrigo Mansilla-Vivar
Rodrigo Mansilla-Vivar
NANoelia Alonso-Lázaro
Noelia Alonso-Lázaro
LALidia Argüello-Viudez
Lidia Argüello-Viudez
MPMarta Ponce-Romero
Marta Ponce-Romero
MBMarco Bustamante Balén
Marco Bustamante Balén
VPVicente Pons-Beltrán
Vicente Pons-Beltrán

28 April 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
SSSarmed S. Sami
Sarmed S. Sami
KRKrish Ragunath
Krish Ragunath
EWEmilie A. Wilkes
Emilie A. Wilkes
MJMartin James
Martin James
RMRodrigo Mansilla-Vivar
Rodrigo Mansilla-Vivar
NGNeil Guha
Neil Guha

7 August 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
RMRodrigo Mansilla-Vivar
Rodrigo Mansilla-Vivar
CSCarolina A. Serrano
Carolina A. Serrano
CPCamila Palma
Camila Palma
MVMacarena Vera
Macarena Vera
CHCaroll Hernandez
Caroll Hernandez
AEAlberto Espino
Alberto Espino

30 May 2026 in United European Gastroenterology Journal
Verified
Journal Article
Open access
KCKarina Cárdenas‐Jaén
Karina Cárdenas‐Jaén
Lucía GuilabertLucía Guilabert
Lucía Guilabert
EMEmma Martínez‐Moneo
Emma Martínez‐Moneo
CMCarla Mancilla
Carla Mancilla
MBMiguel Bispo
Miguel Bispo
EDEnrique de-Madaria
Enrique de-Madaria
Introduction: Acute pancreatitis (AP) is a major cause of gastrointestinal hospitalizations worldwide. Although typically self‐limiting, up to one‐third of cases develop complications associated with increased morbidity and mortality. Despite recent advances that have improved outcomes, clinical heterogeneity necessitates updated, evidence‐based guidance. In addition, there remains a need to improve the implementation of evidence‐based recommendations across Ibero‐Latin American countries by bringing together diverse scientific societies and regional experts to enhance applicability and the dissemination of best practices. This guideline offers comprehensive recommendations for both mild and complicated AP diagnosis and management. Methods: Questions on AP management were addressed by expert teams comprising one coordinator and four pancreatology specialists from the Iberian Peninsula and Latin America. For each question, a systematic review was conducted using PubMed, Embase, and the Cochrane Library, focusing on randomized controlled trials and systematic reviews published between January 1979 and March 2024 in English, Spanish, or Portuguese. In the absence of high‐quality evidence, the search was expanded to include observational studies. Recommendations were formulated using the GRADE system and submitted to an expert panel for consensus; unresolved questions were revised and resubmitted until consensus was reached. Results: Twenty evidence‐based recommendations were developed, addressing key aspects of AP management, including definitions, diagnostic criteria, etiological assessment, initial management, management of local complications, splanchnic vein thrombosis, abdominal compartment syndrome, indications for intensive care admission, antibiotic use, early endoscopic retrograde cholangiopancreatography, timing of cholecystectomy, strategies for detecting choledocholithiasis, and the management of pancreatic function insufficiency. Each recommendation included a statement, the level of evidence, the strength of the recommendation, and a summary of the supporting evidence. Conclusion: The iLATAM guidelines are the first Ibero‐Latin American clinical practice guidelines for AP. They provide evidence‐based recommendations integrating medical, endoscopic, and surgical approaches, with the aim of promoting consistent, high‐quality care across diverse healthcare settings. Trail Registration: In alignment with international standards for transparency and methodological rigor, the methodological protocol for this guideline was registered in PROSPERO (International Prospective Register of Systematic Reviews) on July 23, 2022 (Registration ID: CRD42022345788).

22 January 2016 in Endoscopy
Verified
Journal Article
Closed access
PDF file
RMRodrigo Mansilla-Vivar
Rodrigo Mansilla-Vivar
ECElizabeth Sainza Caballero
Elizabeth Sainza Caballero
CDCristina Saldaña Dueñas
Cristina Saldaña Dueñas
LOLaura Casanova Ortiz
Laura Casanova Ortiz
IFIgnacio Fernandez-Urien
Ignacio Fernandez-Urien
JCJuan J. Vila Costas
Juan J. Vila Costas
A 37-year-old woman had a history of cholelithiasis and choledocholithiasis in 2007, and cholecystectomy and endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy had been performed. She was admitted to our unit with a 10-day history of upper abdominal pain that radiated into the back. She reported no weight loss, no fever, and no change in bowel habit. On questioning, the patient reported that she had travelled to Peru 6 months previously, and had probably ingested contaminated water. Laboratory tests showed minimal elevation of serum amylase, and normal findings for lipase, hepatic function, complete blood count, electrolyte levels, and blood chemistry. Abdominal ultrasound revealed hepatic steatosis. Mild pain persisted despite treatment with antispasmodics. After 5 days, upper gastrointestinal endoscopy was performed and showed antral chronic gastritis. Endosonography showed normal large blood vessels. The uncinate process, head, isthmus, body, and tail of the pancreas showed normal appearances, as did the size and shape of the papilla and pancreatic duct. The common bile duct was dilated to 9 mm, and a tubular entity about 4 mm in diameter was extending through it, from the duodenal lumen to the intrahepatic bile duct. Tubular structures that moved independently were observed ([Fig. 1]). Because the endoscopic appearance was suspicious for parasitic infestation, we exchanged the echoendoscope for a duodenoscope, confirmed the diagnosis ([Fig. 2]), and extracted the specimen completely using a Talon grasping device (US Endoscopy, Mentor, Ohio, USA), observing a parasite of 20 cm in length ([Video 1]). Microbiological study confirmed Ascaris lumbricoides. After extraction of the parasite, the patient reported no abdominal pain. A single dose of albendazole (400 mg) was administered [1] and the patient was discharged. Ascaris lumbricoides is an intestinal nematode (roundworm), producing a globally distributed helminthic infection. The majority of infections occur in the developing countries of Asia and Latin America [2]. The symptoms and complications of infection can be pulmonary and hypersensitivity manifestations [3], intestinal symptoms and obstruction [4], and hepatobiliary and pancreatic [5]. Endoscopy_UCTN_Code_CCL_1AF_2AF_3AZ

13 March 2015 in Frontline Gastroenterology
Verified
Journal Article
Open access
PDF file
JOJ Ortiz-Fernández-Sordo
J Ortiz-Fernández-Sordo
SSS Sami
S Sami
RMRodrigo Mansilla-Vivar
Rodrigo Mansilla-Vivar
JCJ De Caestecker
J De Caestecker
ACA Cole
A Cole
KRKrish Ragunath
Krish Ragunath
Objective Evaluate the incidence of metachronous visible lesions (VLs) in patients referred for radiofrequency ablation (RFA) for early Barrett's neoplasia. Design This study was conducted as part of the service evaluation audit. Setting Tertiary referral centre. Patients All patients with dysplastic Barrett's oesophagus referred for RFA were included for analysis. White light high-resolution endoscopy (HRE), autofluorescence imaging and narrow band imaging were sequentially performed. Endoscopic mucosal resection (EMR) was performed for all VL. Three to six months after EMR, all patients underwent initial RFA and then repeat RFA procedures at three monthly intervals. Interventions All endoscopy reports and final staging by EMR/surgery were evaluated and included for analysis. Results Fifty patients were analysed; median age 73 years, 84% men. 38/50 patients (76%) had a previous EMR due to the presence of VL before referred for ablation; twelve patients had no previous treatment. In total, 151 ablation procedures were performed, median per patient 2.68. Twenty metachronous VL were identified in 14 patients before the first ablation or during the RFA protocol; incidence was 28%. All metachronous lesions were successfully resected by EMR. Upstaging after rescue EMR compared with the initial histology was observed in four patients (28%). Conclusions In total, 28% of patients enrolled in the RFA programme were diagnosed to have metachronous lesions. This high-incidence rate highlights the importance of a meticulous examination to identify and resect any VL before every ablation session. RFA treatment for early Barrett's neoplasia should be performed in tertiary referral centres with HRE and EMR facilities and expertise.